Have questions? Call for answers.
ACTIMMUNE® (Interferon gamma-1b) demonstrated meaningful reductions in the total number and rate of serious infections in patients with chronic granulomatous disease (CGD).
The treatment effect of ACTIMMUNE® was seen early and maintained for the duration of the study.
In subgroup analyses, ACTIMMUNE® was beneficial regardless of age or type of CGD inheritance. There was a 67% reduction in relative risk of serious infection in patients receiving ACTIMMUNE® compared with placebo across all groups.
‡ A serious event was defined as a serious infection requiring hospitalization and intravenous antibiotics.
§ Statistically significant; P < .05
Treatment with ACTIMMUNE® reduced the number of hospitalization days by 67%.
In patients needing hospitalization, the average length of stay was 33% shorter for those in the ACTIMMUNE® group compared with those in the placebo group (32 vs 48 days, P = .02).
In addition, more than twice as many patients in the placebo group compared with the ACTIMMUNE® group were hospitalized for more than 28 days (13 vs 6 patients).
More than twice as many patients treated with ACTIMMUNE® remained free of serious infection for up to 12 months compared with patients treated with placebo.
77% |
were free of serious infection for up to the 12 months of the study|| |
compared to
30% |
of patients who received placebo (P = .0006) |
*Serious infection was defined as a clinical event requiring hospitalization and intravenous antibiotics.
†United States and Europe.
||Mean duration of ACTIMMUNE® treatment was 8.9 months.
References: 1. ACTIMMUNE® (Interferon gamma-1b) [prescribing information] Horizon. 2. The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med. 1991;324(8):509-516.
ACTIMMUNE® (Interferon gamma-1b) is indicated:
ACTIMMUNE® (Interferon gamma-1b) is indicated: